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Abstract
The objective of the research was to study the frequency of remission in young adults with juvenile idiopathic arthritis
during the transition period from paediatric to adult healthcare and factors contributing to its development.
Materials and methods. In our study, there were included 165 adult patients from different regions of Ukraine diagnosed with
juvenile idiopathic arthritis according to the classification criteria of the International League of Associations for Rheumatology.
All the patients were examined in the Oleksandrivska City Clinical Hospital, Kyiv during 2015-2018. There were assessed the
presence of rheumatoid factor, anti-cyclic citrullinated peptide, antinuclear antibodies, human leukocyte antigen B27, disease
duration, disease activity (the Juvenile Arthritis Disease Activity Score-10 and the Disease Activity Score-28), C-reactive
protein, past medical history, quality of life (the 36-Item Short Form Health Survey), the degree of depression (the Patient
Health Questionnaire-9) and alexithymia (the 20-item Toronto Alexithymia Scale). In all the patients, bone mineral density was
studied using dual-energy x-ray absorptiometry with the evaluation of T- and Z-scores in different regions of the skeleton. The
disease was considered inactive at the Disease Activity Score-28 <2.6 and the Juvenile Arthritis Disease Activity Score-10
<1 and <2 for oligoarticular and polyarticular variants of juvenile idiopathic arthritis, respectively.
Results. All the patients were divided into 2 groups: Group I included 136 (82.4%) patients with active disease at the time of
examination; Group II comprised 29 (17.6%) patients who achieved remission according to the Disease Activity Score-28 or
the Juvenile Arthritis Disease Activity Score-10. In Group I, females prevailed accounting for 58.1% of patients as compared
to Group II (31.0%). Disease duration was longer in patients of Group I (p<0.01); however, they did not differ from patients
of Group II in age at disease onset and the International League of Associations for Rheumatology variants of juvenile
idiopathic arthritis. In Group II, lesions involving more than 3 joints (p<0.01), hand arthritis (p<0.01), symmetric arthritis
(p<0.01), enthesitis (p<0.01), spinal pain (p<0.01) were observed less frequently. Fewer patients required joint replacement
(p<0.01); the number of deformed and painful joints (p<0.05, p<0.001, respectively) was smaller. However, there was no
difference in the level of rheumatoid factor, anti-cyclic citrullinated peptide, antinuclear antibodies, and the presence of human
leukocyte antigen B27. The achievement of remission improved physical well-being of patients (the physical component score,
p<0.001), although overall mental well-being (the mental component score) did not change according to the 36-Item Short
Form Health Survey. In patients with remission, the indicators of physical functioning (p<0.001), role functioning (p<0.001),
social functioning (p<0.001), bodily pain (p<0.001), general health (p<0.001), mental health (p<0.001) improved. There was
observed a reduction in the level of depression to the normal one according to the Patient Health Questionnaire-9 (p<0.05);
however, in both groups, there were observed elevated levels of alexithymia. Both groups did not differ in the frequency of
immunobiological therapy prescription; however, the results should be intepreted with caution, since only 5 (17.1%) patients
in Group II received immunobiological therapy earlier or at the time of examination. In Group II, patients did not receive
glucocorticoids at the time of examination (p<0.001) and earlier more often (p<0.001). Both groups did not differ in both the
duration of treatment with disease-modifying antirheumatic drugs and the doses of methotrexate and sulfasalazine.
Conclusions. Remission of juvenile idiopathic arthritis was detected in 17.6% of the surveyed young adult patients from
different regions of Ukraine during the transition period from paediatric to adult healthcare, that indicated that in most cases
the goal of treat-to-target strategy was not achieved. Patients with active disease often developed joint deformities and
required their replacement; they had worse physical well-being according to the 36-Item Short Form Health Survey, although
mental well-being was affected in both patients with active disease and those with remission, which may be due to high levels
of alexithymia in both groups. Patients with active disease had higher levels of depression according to the Patient Health
Questionnaire-9, whereas patients in remission showed no depression.
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Problem statement and analysis of the
recent research
The clinical course of juvenile idiopathic (rheumatoid) arthri-
tis (JIA)[1] in adulthood and at the stage of transition from
paediatric to adult healthcare, as well as the frequency of
remission have not been sufficiently studied yet [2, 4]. The
clinical course of JIA in childhood is known to be both mono-
cyclic and polycyclic and may be characterized by long-term
remissions [3, 7]. However, the clinical course of JIA in adult-
hood and the features of the development and diagnosis of
remission in adult patients have been insufficiently studied.
According to the International League of Associations for
Rheumatology (ILAR) prognosis, patients with oligoarticular
JIA go into remission most frequently. Adult rheumatolo-
gists are not always aware of this JIA subtype, as the clinical
course of rheumatoid disease has no equals in adulthood.
Oligoarticular JIA is characterized by the presence of positive
antinuclear antibodies (ANA). It occurs most often in girls
at the age of 2-6 years with the development of arthritis in-
volving less than 4 joints. This variant is characterized by the
favourable prognosis and long-term remissions. In other JIA
variants, remission occurs more rarely. Although, a signifi-
cant proportion of young adults with JIA present persistent
disease activity, no unified approaches to its measurement
have been developed yet [5, 6, 7, 11]. The Juvenile Arthritis
Disease Activity Score (JADAS) [12] is known to be used
for assessing disease activity in childhood. It has different
variations depending on the number and location of the joints
considered while calculating the score: JADAS-71, JADAS-
27, JADAS-10 or cJADAS (JADAS-3). This scale allows
determining disease activity in JIA by estimation of the sum
of the following parameters: the physician’s global assess-
ment of disease activity (measured on a 0-10 visual analog
scale (VAS)); the patient’s/parent’s global assessment of well-
being (measured on a 0-10 VAS); the assessment of 71, 27 or
10 involved joints, joint count (71, 27, 10), active joint count
(JADAS-71, JADAS-27 and JADAS-10, respectively); normal-
ized C-reactive protein (C-RP) or erythrocyte sedimentation
rate (ESR) measured by the Westergren method. Recently, in
paediatric practice, the JADAS-3 which excludes the deter-
mination of the ESR or C-RP has been used. It is calculated
using the three aforementioned clinical indicators. According
to the JADAS-10, disease activity in childhood is assessed
as follows: for oligoarthritis and polyarthritis, the disease is
considered inactive at the JADAS-10<1; oligoarthritis activ-
ity is low at the JADAS-10<2, polyarthritis activity is low
at the JADAS-10<3.8; oligoarthritis activity is moderate at
the JADAS-10 of 2.1-4.2, polyarthritis activity is moderate
at the JADAS-10 of 3.9-10.5; oligoarthritis activity is consid-
ered to be high at the JADAS-10>4.2, polyarthritis activity is
considered to be high at the JADAS-10>10.5 [12].
In 2006, A. Ravelli, and A. Martini proposed to differenti-
ate between ”inactive disease” and ”clinical remission” [10].
JIA is considered inactive when there are no joints with active
arthritis, no fever, rash, serositis, splenomegaly, or generalized
lymphadenopathy attributable to JIA, no active uveitis; nor-
mal ESR or C-RP; physician’s global assessment of disease
activity indicates no disease activity.
For the concept of ”achieving clinical remission” two
options were proposed:
1. Clinical remission with medication. The criteria for
inactive disease must be met for a minimum of 6 con-
secutive months while the patient is taking medication
2. Clinical remission without medication. The criteria
for inactive disease must be met for a minimum of 12
consecutive months while the patient is not taking any
anti-arthritis and anti-uveitis medications. There are
certain criteria for determining the absence of disease
activity, namely the absence of the joints with active
arthritis, fever, rash, serositis, splenomegaly, or gen-
eralized lymphadenopathy attributable to JIA, uveitis;
normal ESR or CRP or the absence of association of
their increase with JIA, duration of morning stiffness
<15 min.
However, remission in JIA is a controversial issue being in-
sufficiently studied [9, 11]. There is no consensus method
of assessing JIA activity and remission in adulthood, and the
factors associated with remission development have not been
sufficiently study as well.
The objective of the research was to study the frequency of
remission in young adult patients during the transition period
from paediatric to adult healthcare and in adulthood as well
as factors contributing to its development.
1. Materials and methods
The study included 165 adult patients with JIA who were trans-
ferred to adult rheumatology services. This group included
patients residing in different regions of Ukraine who were
diagnosed with JIA during 1984-2013. Inclusion criteria were
as follows: patients with JIA according to the ILAR criteria
[8]; patients over 18 years of age without severe comorbidity
whose diagnosis of JIA was reviewed retrospectively. Pa-
tients with disease duration of less than 3 years were excluded
from the study. There was conducted a retrospective analysis
of the patients’ medical records including the patient’s age
at disease onset, the time elapsed between the first clinical
manifestations and the time of diagnosis, disease activity at
disease onset and treatment received in childhood. All the
patients over 18 years of age were examined as outpatients
or inpatients in the Oleksandrivska City Clinical Hospital,
Kyiv from April 2015 to Mai 2018. There were assessed dis-
ease duration, the ILAR variant at disease onset, the presence
of rheumatoid factor (RF), anti-cyclic citrullinated peptide
(A-CCP), ANA, human leukocyte antigen B27 (HLA-B27),
disease activity according to the JADAS-10 and the Disease
Activity Score-28 (DAS-28), C-RP, treatment received by the
patient at the time of examination and past medical history
including immunobiological therapy (IBT). Quality of life
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(QoL) in patients with JIA was evaluated using the 36-Item
Short Form Health Survey (SF-36). The degree of depression
was assessed using the Patient Health Questionnaire-9 (the
PHQ-9) and the degree of alexithymia was assessed using
the 20-item Toronto Alexithymia Scale (TAS-20). In all the
patients, bone mineral density (BMD) was studied using dual-
energy x-ray absorptiometry with the evaluation of T- and
Z-scores in different regions of the skeleton.
The presence of active disease and remission in adulthood
was assessed. The disease was considered inactive at the DAS-
28 <2.6 and the JADAS-10 <1 and <2 for oligoarticular and
polyarticular variants of JIA, respectively, that were assessed
in patients simultaneously.
2. Results and discussion
All the patients were divided into 2 groups: Group I included
136 (82.4%) patients with active disease at the time of ex-
amination by an adult rheumatologist; Group II comprised
29 (17.6%) patients who achieved remission according to the
DAS-28 or the JADAS-10. Table 1 presents general charac-
teristics of young adult patients with JIA. Thus, patients who
achieved remission did not differ in age while carrying out
the research; however, in the group of active disease, women
prevailed accounting for 58.1% of patients as compared to the
group of patients who achieved remission (31.0%). Patients of
both groups did not differ in height, although they had larger
body weight (p<0.01) and, accordingly, higher body mass
index (BMI); however, it was within the normal BMI range.
Disease duration was longer in patients of Group I (p<0.01);
however, they did not differ from patients of Group II in age
at disease onset and the ILAR variants of JIA.
The analysis of clinical manifestations (Table 2) revealed
that in patients of Group II, lesions involving more than 3
joints (p<0.01), hand arthritis (p<0.01), symmetric arthri-
tis (p<0.01), enthesitis (p<0.01), spinal pain (p<0.01) were
observed less frequently. Fewer patients required joint replace-
ment (p<0.01); the number of deformed and painful joints
(p<0.05, p<0.001, respectively) was accordingly smaller.
When examining patients of Group II, there were observed no
X-ray changes, or they were more often diagnosed with X-ray
stage I according to the criteria proposed by Sharp (p<0.001).
Patients of both groups differed in the DAS-28, the JADAS,
the physician’s/patient’s global health assessment (measured
on a 0-10 VAS), C-RP and ESR (all p-values <0.01), that are
responsible for the activity of the process (Table 3). However,
there was no difference in the levels of RF, A-CCP, ANA and
the presence of HLA-B27. There were no differences in the
levels of total cholesterol, low-density lipoproteins (LDL),
and glucose serving as risk factors for atherosclerosis.
BMD is known to reduce more often in patients with
chronic inflammatory diseases. Therefore, we studied serum
levels of 25-hydroxyvitamin D (25 (OH) D), total and ionized
calcium in patients of both groups; however, there were ob-
served no statistically significant differences between the two
groups.
Table 4 presents the results of studying BMD in young
adult patients with JIA who achieved remission and those with
active disease. There were some differences in the lumbar
spine (LS) by Z-score, the femoral neck (FN) by BMD and
Z-score and the ultra-distal region of the forearm by BMD
(all p-values<0.05).
The analysis of QoL, alexithymia and depression in young
adult patients with JIA who achieved remission and those
with active disease (Table 5) revealed significant impact of
active disease. Thus, the achievement of remission improved
physical well-being of patients (the physical component score
(PCS), p<0.001), although overall mental well-being (the
mental component score (MCS)) did not change. Accord-
ing to the SF-36, in patients with remission, the indicators
of physical functioning (PF) (p<0.001), role functioning
(RF) (p<0.001), social functioning (SF) (p<0.001), bodily
pain (BP) (p<0.001), general health (GH) (p<0.001), mental
health (MH) (p<0.001) improved. There was observed a re-
duction in the level of depression to the normal one according
to the PHQ-9 (p<0.05); however, in both groups, there were
observed elevated levels of alexithymia and they did not differ
in this indicator.
The analysis of drug therapy in young adult patients with
JIA who achieved remission and those with active disease
(Table 6) revealed that they did not differ in the frequency of
IBT prescription; however, the results should be intepreted
with caution, since among patients who achieved remission,
only 5 (17.1%) individuals received IBT earlier or at the time
of examination. However, patients with JIA who achieved
remission turned out more often not to receive glucocorti-
coids (GCs) at the time of examination (p<0.001) and earlier
(p<0.001). Both groups did not differ in both the duration
of basic therapy with disease-modifying antirheumatic drugs
(DMARDS) and the doses of methotrexate and sulfasalazine.
3. Conclusions
Thus, according to the results of our study, remission was
detected in 17.6% of the surveyed young adult patients from
different regions of Ukraine during the transition period from
paediatric to adult healthcare and in adulthood, that indicated
that in most cases the goal of treat-to-target strategy was not
achieved. Patients with active disease often developed joint
deformities and required their replacement; they had worse
physical well-being according to the SF-36, although mental
well-being was affected in both patients with active disease
and those with remission, which may be due to high levels of
alexithymia in both groups. Patients with active disease had
higher levels of depression according to the PHQ-9, whereas
patients in remission showed no depression.
Prospects for further research
Further studies of factors contributing to the development of
JIA remission in adulthood considering past IBT are essential.
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Table 1. Characteristics of young adult patients with JIA who achieved remission and those with active disease (the median
(minimum-maximum) [the lower and upper quartiles])
Clinical manifestations Active disease (n=136) Remission (n=29) p
Age at the moment of examination, years 23.3±7.5 20.7±3.2 0.252
Age at JIA onset, years 9.0±4.9 10.2±4.9 0.209
Gender (males/females) 79 (58.1%) / 57 (41.9%) 9 (31.0%) / 20 (69.0%) 0.008*
Height, m 1.7±0.1 1.7±0.1 0.095
Body weight, kg 61.5±13.8 68.9±12.0 0.008*
BMI, kg/m2 21.1±3.7 22.9±2.7 0.008*
Disease duration 13.5 (7; 18.2) 7.5 (4.2; 12.7) 0.006*
ILAR variant of JIA
RF (+) polyarthritis 12 (8.8%) 0 (0%)
0.305
Persistent oligoarthritis 31 (22.8%) 11 (39.3%)
Extended oligoarthritis 17 (12.5%) 4 (14.3%)
RF (-) polyarthritis 35 (25.7%) 4 (14.3%)
Systemic arthritis 19 (14%) 3 (10.7%)
Enthesitis-related arthritis 21 (15.4%) 6 (21.4%)
Psoriatic arthritis 1 (0.7%) 0 (0%)
Table 2. Clinical manifestations in young adult patients with JIA who achieved remission (the median (minimum-maximum)
[the lower and upper quartiles])
Clinical manifestations Active disease (n=136) Remission(n=29) p
Morning stiffness, min 10 (5; 30) [0; 240] 5 (0; 7.5) [0; 30] 0.001*
Systemic manifestations 24 (17.6%) 2 (6.9%) 0.116
Arthritis >3 joints 68 (50%) 1 (3.4%) 0.001*
Hand arthritis 49 (36%) 1 (3.4%) 0.001*
Symmetric arthritis 47 (34.6%) 1 (3.4%) 0.001*
Lymphadenopathy 11 (8.1%) 1 (3.4%) 0.336
Uveitis 19 (14%) 3 (10.3%) 0.451
Enterocolitis 2 (1.5%) 0 (0%) 0.678
The presence of arthritis
0.001*
Oligoarthritis 75 (55.1%) 10 (34.5%)
Monoarthritis 3 (2.2%) 4 (13.8%)
Polyarthritis 43 (31.6%) 0 (0%)
Absence of arthritis 15 (11%) 15 (51.7%)
Enthesitis 31 (22.8%) 0 (0%) 0.004*
Dactylitis 6 (4.4%) 0 (0%) 0.247
Sacroilitis 32 (23.5%) 4 (13.8%) 0.179
Back pain 74 (54.4%) 5 (17.2%) 0.001*
Need for joint replacement 41 (30.1%) 1 (3.4%) 0.001*
Painful joints (the number) 2 (1; 5) [0; 22] 0 (0; 0) [0; 3] 0.001*
Deformed joints, anky-
loses/orthopedic prostheses
(the number)
0 (0; 1) [0; 11] 0 (0; 0) [0; 4] 0.030*
Swollen joints (the number) 1 (0; 2) [0; 16] 0 (0; 0) [0; 1] 0.001*
X-ray stage 1 (1; 3) [0; 4] 1 (0; 1) [0; 2] 0.001*
Functional failure of joints
0.001*
0 10 (7.4%) 14 (48.3%)
1 51 (37.5%) 15 (51.7%)
2 65 (47.8%) 0 (0%)
3 10 (7.4%) 0 (0%)
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Table 3. Disease activity and laboratory findings of young adult patients with JIA who achieved remission and those with
active disease (the median (minimum-maximum) [the lower and upper quartiles])
Parameter Active disease (n=136) Remission (n=29) p
DAS-28 3.4±1.4 1.6±0.7 0.001*
JADAS 8 (5; 15) [1; 34] 1 (0; 3.5) [0; 13] 0.001*
VAS (patient), mm 40 (30; 60) [0; 90] 10 (2.5; 20) [0; 40] 0.001*
VAS (physician), mm 40 (20; 50) [0; 90] 0 (0; 10) [0; 30] 0.001*
C-RP 6 (4; 24) [0; 284] 4 (4; 4) [0; 4] 0.001*
ESR, mm/hour 14 (6; 30) [2; 70] 5 (3; 7) [1; 17] 0.001*
RF 0 (0; 0) [0; 64] 0 (0; 0) [0; 1] 0.358
A-CCP 2 (2; 2) [1; 7.1] 2 (2; 2) [1; 2] 0.460
ANA 16 (11.7%) 3 (10.3%) 0.161
HLA-B27 41 (30.1%) 6 (20.7%) 0.156
LDL, mmol/l 2.6±1.1 2.2±0.8 0.848
Cholesterol, mmol/l 4.6±1.1 4.1±1.1 0.111
Glucose, mmol/l 4.8±0.6 4.7±0.7 0.856
25(OH)D, ng/ml 18 (14.2; 23.1) [6.1; 48.5] 22.8 (20; 23) [20; 28.3] 0.189
Albumin, g/l 39.1 (36; 46) [2.5; 49.3] 46 (39.3; 58) [39.3; 50.3] 0.179
Total calcium, mmol/l 2.4 (2.3; 2.4) [1.3; 2.5] 2.3 (1.4; 2.7) [1.2; 2.9] 0.511
Ionized calcium, mmol/l 2.5 (2.3; 2.5) [2.3; 2.5] - -
Table 4. BMD in young adult patients with JIA who achieved remission and those with active disease (the median
(minimum-maximum) [the lower and upper quartiles])
Parameter Active disease (n=136) Remission (n=29) p
LS BMD, g/cm2 1.04 (0.9; 1.21) [0.36; 1.39] 1.13 (1; 1.28) [0.98; 1.7] 0.090
T-score in the LS -1.02 (-1.5; 0.72) [-3; 1.8] - -
Z-score in the LS -0.9 (-1.9; 0.32) [-6.3; 2.3] -0.09 (-0.65; 0.84) [-0.8; 3.5] 0.031*
FN BMD, g/cm2 0.91 (0.8; 1.03) [0.24; 1.32] 0.99 (0.95; 1.31) [0.86; 1.35] 0.042*
T-score in the FN -0.8 (-1.6; -0.3) [-3.1; 1.14] - -
Z-score in the FN -0.8 (-1.38; -0.1) [-5.3; 1.97] 0.35 (0.15; 0.63) [0.1; 0.7] 0.017*
Whole skeleton BMD g/cm2 0.81 (0.66; 0.89) [0.43; 1.06] 0.9 (0.77; 1.04) [0.75; 1.06] 0.098
T-score in the whole skeleton -0.35 (-1.83; 0.18) [-2.4; 1.83] - -
Z-score in the whole skeleton -0.35 (-1.5; 0.19) [-2.9; 2.38] -0.2 (-0.2; -0.2) [-0.2; -0,2] 0.848
Ultra-distal forearm BMD g/cm2 1.02 (0.88; 1.11) [0.66; 1.29] 1.14 (0.97; 1.28) [0.93; 1.29] 0.048*
T-score in the ultra-distal region of the forearm -0.45 (-1.58; 0.32) [-2.3; 2.26] -0.4 (-0.4; -0.4) [-0.4; -0.4] 0.942
Z-score in the ultra-distal region of the forearm -0.5 (-1.25; 0.39) [-4.8; 2.76] -0.3 (-0.6;) [-0.6; 0.3] 0.699
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